Help your patients overcome the injection barrier.


Image

Double click to edit

Start the conversation about Victoza® with these 3 simple steps

Download the 3 simple steps brochure to start the conversation about Victoza®.


Use these 3 steps to navigate the injection conversation.

Describe the attributes of Victoza®

Noninsulin, once-daily dosing, independent of meals

Lowers A1C with the additional benefits of weight loss and a low rate of hypoglycemiaa

Review the Medication Guide, including Important Safety Information, with your patients

Image

Double click to edit

Demonstrate how to use the Victoza® pen

Deliver the first dose in the office

A prefilled, disposable pen; no resuspension necessary

Image

Double click to edit

Encourage your patients to enroll in VictozaCare™

Enrollment in VictozaCare™ 
automatically includes initiation support, plus ongoing education and resources

 

aVictoza® is not indicated for chronic weight management, and weight change was a secondary endpoint in clinical trials.


In studies of patients' perceptions:


80%

surveyed were open to self-injection when the potential clinical benefits were explained.1,b

90%

considered Victoza® pen easy to learn how to use when demonstrating into a pillow.2,c

MOST

experienced little or no pain with a 32G Tip 6 mm needle.3,d

Image

Double click to edit


victoza-pen

Please see complete Instructions for Use.
Needles are sold separately and may require a prescription in some states.



Explore these Victoza® resources


The Victoza® pen

Show patients how to dial, dose, and deliver with the Victoza® pen.

bAn online market research survey of US residents with type 2 diabetes, aged 40 to 68 years (N=797, of whom 558 were noninsulin users). Two waves of reporting were aggregated into 1 reportable base size.1

cA randomized, multicenter, open‐label, single‐visit test to evaluate the usability of 3 Victoza® pens following subject review of the Victoza® Instructions for Use. Subjects with uncorrected visual impairment, limited manual dexterity, motor impairment, mental incapacity, or psychiatric disorder were excluded. Eligible subjects (N=90) were randomized to 1 of 6 pen/dose combinations and asked to read the Victoza® Instructions for Use and independently perform a specified injection into a foam pillow. After reading the Victoza® Instructions for Use and completing the task assigned, subjects completed the Victoza® Usability Questionnaire. The questionnaire included questions pertaining to how easy or difficult it was to prepare the pen, dial the dose and read the scale, deliver the dose, and learn to use the pen.2 

dA randomized, open‐label, 2‐period crossover trial in insulin‐treated patients (N=119) with type 1 or type 2 diabetes. Patients used both the NovoFine® 32G Tip (6 mm) and the NovoFine® 30G (8 mm) with the FlexPen®. Patients injected themselves with their usual insulin with 1 needle type followed by the alternate for 7 to 14 days. Needle preference and perceptions of pain, handling, and acceptance were assessed using a questionnaire after use of each needle.3 


References: 1. Data on file. 80% open to self-injection. Novo Nordisk Inc., Plainsboro, NJ. 2. Data on file. Test ID: Victoza® pen: a randomized, multicenter, open-label usability test of the Victoza® 1.2 mg, 1.2/1.8 mg and 1.8 mg pens in male and female subjects with type 2 diabetes mellitus. Novo Nordisk Inc., Plainsboro, NJ. 3. McKay M, Compion G, Lytzen L. A comparison of insulin injection needles on patients’ perceptions of pain, handling, and acceptability: a randomized, open-label, crossover study in subjects with diabetes. Diabetes Technol Ther. 2009;1(3):195-201.    

 

Selected Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS

  • Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Victoza® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined.
  • Victoza® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Victoza®and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Victoza®.

Indication and Limitations of Use

Victoza® (liraglutide) injection 1.2 mg or 1.8 mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

  • Victoza® is not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise.
  • Acute pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with Victoza® postmarketing. It is unknown whether patients with a history of pancreatitis are at increased risk for pancreatitis while using Victoza®; consider other antidiabetic therapies for these patients.
  • Victoza® is not a substitute for insulin and should not be used in patients with type 1 diabetes mellitus or diabetic ketoacidosis.
  • Concurrent use with prandial insulin has not been studied.

Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS

  • Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Victoza® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined.
  • Victoza® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Victoza®and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Victoza®.

Contraindications

  • Victoza® is contraindicated in patients with a prior serious hypersensitivity reaction to Victoza® or to any of the product components.

Warnings and Precautions

  • Risk of Thyroid C-cell Tumors: Patients should be referred to an endocrinologist for further evaluation if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging.
  • Pancreatitis: Acute pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with Victoza® postmarketing. Observe patients carefully for signs and symptoms of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back with or without vomiting). If pancreatitis is suspected, discontinue Victoza® promptly and if pancreatitis is confirmed, do not restart. Consider other antidiabetic therapies in patients with a history of pancreatitis.
  • Never Share a Victoza® Pen Between Patients, even if the needle is changed. Pen-sharing poses a risk for transmission of blood-borne pathogens.
  • Hypoglycemia: When Victoza® is used with an insulin secretagogue (eg, a sulfonylurea) or insulin, serious hypoglycemia can occur. Consider lowering the dose of the insulin secretagogue or insulin to reduce the risk of hypoglycemia.
  • Renal Impairment: Acute renal failure and worsening of chronic renal failure, which may sometimes require hemodialysis, have been reported postmarketing, usually in association with nausea, vomiting, diarrhea, or dehydration. Use caution when initiating or escalating doses of Victoza® in patients with renal impairment.
  • Hypersensitivity Reactions: Serious hypersensitivity reactions (eg, anaphylaxis and angioedema) have been reported postmarketing. If symptoms of hypersensitivity reactions occur, patients must stop taking Victoza® and promptly seek medical advice.
  • Macrovascular Outcomes: There have been no studies establishing conclusive evidence of macrovascular risk reduction with Victoza® or any other antidiabetic drug.

Adverse Reactions

  • The most common adverse reactions, reported in ≥5% of patients treated with Victoza® and more commonly than in patients treated with placebo, are nausea, diarrhea, headache, and vomiting. Immunogenicity-related events, including urticaria, were more common among Victoza®-treated patients (0.8%) than among comparator-treated patients (0.4%) in clinical trials.

Drug Interactions

  • Victoza® causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with Victoza®.

Use in Specific Populations

  • Victoza® has not been studied in patients with type 2 diabetes below 18 years of age and is not recommended for use in pediatric patients.
  • Victoza® slows gastric emptying. Victoza® has not been studied in patients with preexisting gastroparesis.

Additional Important Safety Information

In 5 placebo-controlled clinical trials of at least 26 weeks’ duration, hypoglycemia requiring the assistance of another person for treatment occurred in 8 Victoza®-treated patients (7.5 events per 1000 patient-years). Of these 8 Victoza®-treated patients, 7 patients were concomitantly using a sulfonylurea.

In the pool of 5 placebo-controlled clinical trials, withdrawals due to gastrointestinal adverse reactions occurred in 4.3% of Victoza®-treated patients and 0.5% of placebo-treated patients. Withdrawal due to gastrointestinal adverse events mainly occurred during the first 2 to 3 months of the trials.

Please click here for Prescribing Information.